肺移植受者SARS-CoV-2刺突抗体水平与非免疫抑制人群抗体谱的比较
本研究定量比较肺移植受者(LTR)与非免疫抑制人群的血清抗刺突受体结合域抗体水平。对照者在初次接种、轻症COVID-19、轻症后接种一剂或重症COVID-19后呈现稳健应答谱;LTR在初次接种后应答显著减弱,第三剂「加强」仅轻微提升,但LTR中COVID-19幸存者抗体水平与对照幸存者相当。
要点
- 肺移植受者初次接种后抗体应答显著减弱,第三剂加强仅轻微提升。
- 移植后≥3年及接受加强疫苗剂量与更高的接种抗体水平相关。
- LTR中COVID-19幸存者抗体水平与对照COVID-19幸存者相当。
核心结论
- 肺移植受者对初次接种的抗体应答显著减弱,第三剂加强仅轻微提升。
- 更强的抗原刺激可引发稳健的体液免疫。
- 需进一步研究确定修订的接种策略能否复制这些应答。
研究设计与样本
- 研究定量检测健康对照者在初次接种、轻症COVID-19、轻症后接种一剂或重症COVID-19后的血清抗刺突受体结合域抗体。
- 研究评估肺移植受者在初次接种、第三剂「加强」接种或重症COVID-19后的抗体水平。
主要发现
- 对照者从接种到重症COVID-19呈现稳健应答谱。
- 肺移植受者初次接种后应答显著减弱,第三剂加强仅轻微提升。
- 肺移植受者多变量logistic回归显示移植后≥3年及接受加强疫苗剂量与更高的接种抗体水平相关。
- 肺移植受者中COVID-19幸存者抗体水平与对照COVID-19幸存者相当。
局限性
- 需进一步研究确定修订的接种策略能否复制这些应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung transplant recipients (LTRs) are immunosuppressed and at high risk from COVID-19, but meaningful quantitative comparisons of their humoral immunity versus non-immunosuppressed persons are scarce. Serum anti-spike receptor binding domain antibodies were quantified in healthy controls after: primary vaccination, mild COVID-19, one vaccination after mild COVID-19, or severe COVID-19. LTRs were assessed after: primary vaccination, a third "booster" vaccination, or severe COVID-19. Controls showed a spectrum of robust responses from vaccination to severe COVID-19. LTRs exhibited markedly diminished responses to primary vaccination, minimally increased by a third "booster." Multivariable logistic regression of LTRs showed being ≥3 years after transplantation and receiving a booster vaccine dose were associated with higher vaccination antibody levels. However, the LTR COVID-19 survivors had comparable antibody levels to control COVID-19 survivors, suggesting that greater antigenic stimulus can elicit robust humoral immunity. Further study will be required to determine if revised vaccination strategies can replicate these responses.
引用
- Shino MY, Ibarrondo FJ, Yang OO, et al. SARS-CoV-2 spike antibody levels in lung transplantation recipients versus the spectrum in non-immunocompromised persons. Vaccine. 2025. PMID: 39929055. doi:10.1016/j.vaccine.2025.126851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。